Sentences with phrase «drug for lymphoma»

Merck and Bristol - Myers Squibb each have approved immunotherapy drugs, while Gilead Sciences announced Monday it plans to acquire Kite Pharma for $ 11.9 billion, just a few months before the FDA is expected to approve Kite's CAR - T drug for lymphoma on Nov. 29.

Not exact matches

The biotech received Food and Drug Administration (FDA) approval for its drug to treat the rare blood cancer acute myeloid lymphoma (AML), which will be marketed as Idhifa, on TuesDrug Administration (FDA) approval for its drug to treat the rare blood cancer acute myeloid lymphoma (AML), which will be marketed as Idhifa, on Tuesdrug to treat the rare blood cancer acute myeloid lymphoma (AML), which will be marketed as Idhifa, on Tuesday.

The drug may soon find a wider market if it can be shown effective in treating lymphoma and other blood cancers, and the price for those indications may well be different, based on their if value story.

On the other hand, Biogen has its roots in a Cambridge start - up founded in 1978 by MIT and Harvard scientists working in small, separate labs on then - radical theories, pursuing research dead ends and racking up debt until blockbuster drugs for treating leukemia, MS, and non-Hodgkin's lymphoma brought major commercial success.

The new indication puts Kymriah in direct competition with Gilead Sciences» Yescarta, which was approved by the U.S. Food and Drug Administration in October for treatment of adults with diffuse large B - cell lymphoma who have failed to respond to other treatments.

The U.S. Food and Drug Administration (FDA) is expected to decide by Nov. 29 whether to approve Kite's CAR T, axi - cel, for treatment of adults with advanced lymphoma.

The drug, which was first approved last August for patients under 25 with B - cell precursor acute lymphoblastic leukemia, is now OK» ed to treat large B - cell lymphoma.

Triphase Accelerator Corporation announced a new strategic collaboration with Celgene Corporation, that provides Celgene with an option to acquire all Triphase Accelerator's assets relating to TRPH 222 (CD22 - 4AP), an antibody - drug conjugate in development for lymphoma.

Dozens of trials are underway, and two CAR - T cell products, for childhood and young adult ALL and aggressive B - cell lymphoma, may be approved later this year by the U.S. Food and Drug Administration (FDA).

The drug is already approved in many countries as a treatment for some forms of leukemia and lymphoma, under the name Campath.

For example, a drug called ibrutinib has been tested in clinical trials to treat an aggressive form of non-Hodgkin lymphoma, diffuse large B - cell lymphoma (DLBCL).

Torres notes that it will be important to screen for HCV because treatment with antiviral drugs may possibly prevent cancer from ever developing, as reported for liver cancers and non-Hodgkin's lymphoma.

The researchers studied a class of anti-cancer drugs called BET inhibitors, which are considered promising new drugs for the treatment of blood cancers such as leukemias and lymphomas.

Though unintentional, Ding said the analysis provides an explanation for why investigational drugs that inhibit a protein called BTK have been effective in treating patients with lymphoma.

The therapy is approved by the U.S. Food and Drug Administration for relapsed or treatment - resistant Hodgkin lymphoma, and it is commonly prescribed to patients whose disease has progressed after autologous stem cell transplant, a procedure that replenishes the bone marrow with the patient's own healthy stem cells after therapy.

Nivolumab has been approved by the U.S. Food and Drug Administration for advanced melanoma, lung cancer, kidney cancer and Hodgkin lymphoma.

Starting in 2007, for example, Fan began testing an anti-cancer drug called PAC - 1 (developed by U. of I. chemistry professor Paul Hergenrother) in pet dogs with naturally occurring lymphomas and osteosarcomas.

The drugs are approved for malignancies including melanoma and Hodgkin lymphoma, as well as lung, kidney and bladder cancer.

The changes included reductions in the use and dose of radiation therapy and chemotherapy drugs called anthracyclines for treatment of acute lymphoblastic leukemia (ALL), Hodgkin lymphoma and Wilms tumor, a cancer of the kidneys.

The US Food and Drug Administration (FDA) has granted Priority Review designation for tisagenlecleucel (Kymriah), formerly known as CTL019, for treatment of adult patients with relapsed or refractory diffuse large B - cell lymphoma (DLBCL) who are ineligible for, or have relapsed after, autologous stem cell transplant.

The US Food and Drug Administration (FDA) recently approved the oral Bruton tyrosine kinase (BTK) inhibitor ibrutinib for the treatment of patients with relapsed or refractory marginal zone lymphoma who require systemic therapy and have had at least one prior anti-CD20 therapy.

A phase II trial of brentuximab vedotin (anti-CD30 antibody - drug conjugate) in combination with chemotherapy and radiation therapy for younger patients with advanced Hodgkin lymphoma (NCT01920932).

A phase II trial of brentuximab vedotin (anti-CD30 antibody - drug conjugate) in combination with chemotherapy and radiation therapy for younger patients with advanced Hodgkin lymphoma -LRB-

Abbreviations: Aβ, amyloid β - peptide; AD, Alzheimer's disease; ALS, amyotrophic lateral sclerosis; Ambra1, activating molecule in Beclin -1-regulated autophagy; AMPK, AMP - activated protein kinase; APP, amyloid precursor protein; AR, androgen receptor; Atg, autophagy - related; AV, autophagic vacuole; Bcl, B - cell lymphoma; BH3, Bcl - 2 homology 3; CaMKKβ, Ca2 + - dependent protein kinase kinase β; CHMP2B, charged multivesicular body protein 2B; CMA, chaperone - mediated autophagy; 2 ′ 5 ′ ddA, 2 ′, 5 ′ - dideoxyadenosine; deptor, DEP - domain containing mTOR - interacting protein; DRPLA, dentatorubral pallidoluysian atrophy; 4E - BP1, translation initiation factor 4E - binding protein - 1; Epac, exchange protein directly activated by cAMP; ER, endoplasmic reticulum; ERK1 / 2, extracellular - signal - regulated kinase 1/2; ESCRT, endosomal sorting complex required for transport; FAD, familial AD; FDA, U.S. Food and Drug Administration; FIP200, focal adhesion kinase family - interacting protein of 200 kDa; FoxO3, forkhead box O3; FTD, frontotemporal dementia; FTD3, FTD linked to chromosome 3; GAP, GTPase - activating protein; GR, guanidine retinoid; GSK3, glycogen synthase kinase 3; HD, Huntington's disease; hiPSC, human induced pluripotent stem cell; hVps, mammalian vacuolar protein sorting homologue; IKK, inhibitor of nuclear factor κB kinase; IMPase, inositol monophosphatase; IP3R, Ins (1,4,5) P3 receptor; I1R, imidazoline - 1 receptor; JNK1, c - Jun N - terminal kinase 1; LC3, light chain 3; LD, Lafora disease; L - NAME, NG - nitro - L - arginine methyl ester; LRRK2, leucine - rich repeat kinase 2; MIPS, myo - inositol -1-phosphate synthase; mLST8, mammalian lethal with SEC13 protein 8; MND, motor neuron disease; mTOR, mammalian target of rapamycin; mTORC, mTOR complex; MVB, multivesicular body; NAC, N - acetylcysteine; NBR1, neighbour of BRCA1 gene 1; NOS, nitric oxide synthase; p70S6K, ribosomal protein S6 kinase - 1; PD, Parkinson's disease; PDK1, phosphoinositide - dependent kinase 1; PE, phosphatidylethanolamine; PI3K, phosphoinositide 3 - kinase; PI3KC1a, class Ia PI3K; PI3KC3, class III PI3K; PI3KK, PI3K - related protein kinase; PINK1, PTEN - induced kinase 1; PKA, protein kinase A; PLC, phospholipase C; polyQ, polyglutamine; PS, presenilin; PTEN, phosphatase and tensin homologue deleted from chromosome 10; Rag, Ras - related GTP - binding protein; raptor, regulatory - associated protein of mTOR; Rheb, Ras homologue enriched in brain; rictor, rapamycin - insensitive companion of mTOR; SBMA, spinobulbar muscular atrophy; SCA, spinocerebellar ataxia; SLC, solute carrier; SMER, small - molecule enhancer of rapamycin; SMIR, small - molecule inhibitor of rapamycin; SNARE, N - ethylmaleimide - sensitive factor - attachment protein receptor; SOD1, copper / zinc superoxide dismutase 1; TFEB, transcription factor EB; TOR, target of rapamycin; TSC, tuberous sclerosis complex; ULK1, UNC -51-like kinase 1; UVRAG, UV irradiation resistance - associated gene; VAMP, vesicle - associated membrane protein; v - ATPase, vacuolar H + - ATPase; Vps, vacuolar protein sorting

FDA Approved Ibrutinib for Relapsed, Refractory Marginal Zone Lymphoma: Approval for the use of ibrutinib in patients with relapsed or refractory marginal zone lymphoma was granted by the US Food and Drug Administration for those patients who require systemic therapy who were treated with at least one anti-CD20 Lymphoma: Approval for the use of ibrutinib in patients with relapsed or refractory marginal zone lymphoma was granted by the US Food and Drug Administration for those patients who require systemic therapy who were treated with at least one anti-CD20 lymphoma was granted by the US Food and Drug Administration for those patients who require systemic therapy who were treated with at least one anti-CD20 therapy.

Drew Pardoll, co-director of cancer immunology at the Johns Hopkins School of Medicine, said he expects the FDA to approve immune drugs for bladder cancer, kidney cancer and Hodgkin's lymphoma this year.

Now dozens of such «targeted» drugs are in use for lung and breast tumors, melanoma and lymphomas.

When a similar result was found for lymphomas and leukemias, the EPIC team acknowledged that while the growth - promoting drugs fed to chickens and turkeys could be playing a role, it might also be cancer viruses found in poultry.

There are subplots, like Mr. Damiano being diagnosed with terminal lymphoma and Grace's older sister being involuntarily hospitalized for suspected drug abuse, neither of which the movie follows through on.

Treatment for high grade feline lymphoma usually consists of chemotherapy; a combination of drugs including L - asparaginase, doxorubicin, cyclophosphamide, vincristine, and prednisone are administered over several weeks.

It is for the human drug vinblastine, which is now being tested for its effectiveness in lymphoma.

Purpose of Study: Although vinblastine is commonly used in veterinary cancer therapy, most commonly for treating feline lymphoma, there is currently no information on how the drug is distributed and eliminated in these cats.

The U.S. Food and Drug Administration recently announced that it's given conditional approval for the first new animal drug to treat canine lymphDrug Administration recently announced that it's given conditional approval for the first new animal drug to treat canine lymphdrug to treat canine lymphoma.

Tanovea - CA1 «sconditional approval means that when used according to the label, the drug is safe and has a «reasonable expectation of effectiveness» for treating lymphoma in dogs.

However, they are the two most effective drugs for IBD, and if we don't keep the inflammation under control, then your cat can develop scar tissue, thickened intestines, and in some cases, it can progress to intestinal lymphoma.

Many different drugs have been utilized either singly or in combination for the treatment of lymphomas in dogs.

Re-directed Autologous T cell Therapy for drug resistant or refractory CD20 + B cell lymphoma Overview: In this approach, immune cells (known as T cells) are taken from the peripheral blood, genetically modified in the laboratory to express a receptor that recognizes B cells, and then expanded to produce large numbers of tumor specific T cells outside -LSB-...]

Tags for this Online Resume: Biotechnology, Diagnostic, Pharmaceutical, Marketing, Oncology, Strategy, Brand Planning, Global Marketing, New Product Planning, Pricing, Market Research, Brand Leader, Commercial, Commercialization, Launch, Drug Development, Matrix, Cross Functional, Digital, KOL, Key Opinion Leader, Portfolio, Management, Brand Team, Agency, Diabetes, Cardiovascular, Commercial Strategy, Corporate Affairs, Communications, Hematology, Urology, Neuroscience, phase 2, phase 3, phase II, phase III, Powerpoint, Excel, Word, Part B, Part D, Seattle, Portland, San Francisco, Executive Director, Senior Director, Director, Vice President, Go - To - Market, Value Proposition, Go To Market, Launch Planning, Access, Reimbursement, Payer, Market Development, Market Assessment, Pipeline, In - Line, Brand Management, Coaching, Leadership, Marketing Strategies, Marketing Strategy, Strategic Planning, Autoimmune, Early Stage, Pre-Launch, Pre Launch, Regulatory, Operations, Marketing Plan, Business Plan, Business Development, Market Analysis, Segmentation, Targeting, Companion Diagnostic, Target Product Profile, Pre-Clinical, Competition, Positoning, Branding, Sales, Budget, Sales Management, Communication Plan, Publication Plan, Project Management, Genetic, Genomic, Lifecycle, Long Range, Device, Late Stage, Direct Report, Indirect Report, New Molecular Entities, Competitive, Biopharmaceutical, Medical Device, Non-Promotional, Tactical, Execution, IND, Revenue, Partner, Clinical, Consult, Analytical, Problem Solver, Global, International, Affordable Care Act, Lymphoma, Leukemia, Prostate, Breast, Cancer, OPDP, Promotional, Promotions, Brand, Healthcare, Distribution, Infrastructure, IMS, Priority Review, Experienced, Patient, Consumer